Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial to evaluate pembrolizumab as adjuvant therapy in patients with resected, high-risk stage III melanoma. METHODS: Patients with completely resected stage III melanoma were randomly assigned (with stratification according to cancer stage and geographic region) to receive 200 mg of pembrolizumab (514 patients) or placebo (505 patients) intravenously every 3 weeks for a total of 18 doses (approximately 1 year) or until disease recurrence or unacceptable toxic effects occurred. Recurrence-free survival in the overall intention-to-treat population and in the subgroup of patients with cancer that was positive for the PD-1 ligand (PD-L1) were the primary end points. Safety was also evaluated. RESULTS: At a median follow-up of 15 months, pembrolizumab was associated with significantly longer recurrence-free survival than placebo in the overall intention-to-treat population (1-year rate of recurrence-free survival, 75.4% [95% confidence interval {CI}, 71.3 to 78.9] vs. 61.0% [95% CI, 56.5 to 65.1]; hazard ratio for recurrence or death, 0.57; 98.4% CI, 0.43 to 0.74; P<0.001) and in the subgroup of 853 patients with PD-L1-positive tumors (1-year rate of recurrence-free survival, 77.1% [95% CI, 72.7 to 80.9] in the pembrolizumab group and 62.6% [95% CI, 57.7 to 67.0] in the placebo group; hazard ratio, 0.54; 95% CI, 0.42 to 0.69; P<0.001). Adverse events of grades 3 to 5 that were related to the trial regimen were reported in 14.7% of the patients in the pembrolizumab group and in 3.4% of patients in the placebo group. There was one treatment-related death due to myositis in the pembrolizumab group. CONCLUSIONS: As adjuvant therapy for high-risk stage III melanoma, 200 mg of pembrolizumab administered every 3 weeks for up to 1 year resulted in significantly longer recurrence-free survival than placebo, with no new toxic effects identified. (Funded by Merck; ClinicalTrials.gov number, NCT02362594 ; EudraCT number, 2014-004944-37 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonetheless, adjuvant ICT has been successful in high-risk melanoma, which led to FDA approval (189-193).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [189]
Experimental — accuracy not yet measuredIn the citing paper
“Thyroid events occur in approximately 10% of patients treated with anti-PD-1/PD-L1 monotherapy, and up to 15-20% of those treated with combination PD-1/CTLA-4 blockade (as opposed to only 5% of those treated with ipilimumab monotherapy).9,38”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
In the citing paper
“Any type of irAE occurs in 80-90% of patients, with higher grade events (as categorized by the Common Terminology Criteria for Adverse Events) occurring in 15-20% of patients treated with anti-PD-1/PD-L1 monotherapy, and up to 60% of patients treated with combination of ipilimumab and nivolumab.9”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
In the citing paper
“The combination of ipilimumab and nivolumab has demonstrated enhanced response rates in melanoma, lung cancer, renal cell carcinoma, and mismatch repair deficient colon cancer compared with single agent therapy, although at a cost of increased toxicities (see next section).9–11”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602 · cited 2×
“AJCC denotes American Joint Committee on Cancer 2009 classification, 7th edition.(14) 0.”
BackgroundSelf-citationA Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Self-citationAdjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Self-citationAdjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,490
Self-citationCompletion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613210 · Cited by 1,414
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611299 · Cited by 1,318
Self-citation
Cited by
Items 601–700 of 1,000
NK cell transfer overcomes resistance to PD-(L)1 therapy in aged mice
Hou, J., Xie, S., Gao, J., Jiang, T., Zhu, E., Yang, X., Jin, Z., Long, H., Zhang, A., Yang, F., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00511-9 · Cited by 24
“However, in the KEYNOTE-054 clinical trial, elderly patients exhibited similar OS to younger patients [31].”
ResultImmune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer
Jin, K., Wang, S., Ying, X., Lan, H., Lv, J., Zhang, L.-H., Motallebnezhad, M., & Mou, X. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.02.008 · Cited by 25
Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma
Sabbatino, F., Scognamiglio, G., Liguori, L., Marra, A., Anniciello, A. M., Polcaro, G., Col, J. D., Caputo, A., Peluso, A. L., Botti, G., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.561390 · Cited by 22
Mroue, A., Moujaess, E., Kourié, H. R., Azar, H., Finianos, S., & Chelala, D. N. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103169 · Cited by 22
Boer, F. L., Eikelder, M. T., van Geloven, N., Kapiteijn, E., Gaarenstroom, K. N., Hughes, G., Nooij, L. S., Jozwiak, M., Tjiong, M. Y., Hullu, J. A. D., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.01.018 · Cited by 22
Sue-A-Quan, R., Patel, P. G., Shakfa, N. E., Nyi, M.-P. N., Afriyie-Asante, A., Kang, E. Y., Köbel, M., & Koti, M. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.05.010 · Cited by 22
Han, Y., Wang, J., & Xu, B. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103376 · Cited by 24
Long, G. V., Garnett‐Benson, C., Dolfi, S. C., Ascierto, P. A., Guo, J. X., Tarhini, A. A., Chandra, S., Muñoz‐Couselo, E., Vecchio, M. D., de Melo, A. C., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04032-8 · Cited by 21
Self-citationRepurposing Drugs for Cancer Radiotherapy: Early Successes and Emerging Opportunities
Khan, M. K., Nasti, T. H., Buchwald, Z. S., Weichselbaum, R. R., & Kron, S. J. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000369 · Cited by 22
Namikawa, K., Aung, P. P., Milton, D. R., Tetzlaff, M. T., Torres-Cabala, C. A., Curry, J. L., Nagarajan, P., Ivan, D. S., Ross, M. I., Gershenwald, J. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1194 · Cited by 24
Zucali, P. A., Cordua, N., D’Antonio, F., Borea, F., Perrino, M., Vincenzo, F. D., & Santoro, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568279 · Cited by 25
Toor, K., Middleton, M. R., Chan, K., Amadi, A., Moshyk, A., & Kotapati, S. (2021) · BMC Cancer · doi:10.1186/s12885-020-07538-1 · Cited by 25
Shi, H., & Yang, Y. (2021) · Cancer Medicine · doi:10.1002/cam4.3902 · Cited by 22
Xu, B., Peng, Z., Yan, G., Wang, N., Chen, M., Yao, X., Sun, M., & An, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.726387 · Cited by 23
Chan, K. K., & Bass, A. R. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s282600 · Cited by 29
Gao, Z., Wang, L., Song, Z., Ren, M., Yang, Y., Li, J., Shen, K., Li, Y., Ding, Y., Yang, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954039 · Cited by 22
“Trials of PD-1 blockade focusing on cutaneous melanoma have demonstrated long-term objective response rates (ORR) of approximately 45%, with more than 40% patients surviving for over 5 years (19, 58).”
BackgroundExpert recommendations on diagnostic-therapeutic management of melanoma patients
Rutkowski, P. L., Wysocki, P. J., Kozak, K., Nasierowska-Guttmejer, A. M., Jeziorski, A., Wysocki, W. M., Kalinka‐Warzocha, E., Świtaj, T., Kamińska‐Winciorek, G., Czarnecka, A. M., et al. (2022) · Oncology in Clinical Practice · doi:10.5603/ocp.2021.0042 · Cited by 22
Self-citationKennedy, O. J., Kiciński, M., Valpione, S., Gandini, S., Suciu, S., Blank, C. U., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.04.016 · Cited by 23
Self-citationLodde, G. C., Hassel, J. C., Wulfken, L. M., Meier, F. E., Mohr, P., Kähler, K. C., Hauschild, A., Schilling, B., Loquai, C., Berking, C., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.112957 · Cited by 21
Self-citationAdjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field
Eljilany, I., Castellano, E., & Tarhini, A. A. (2023) · Cancers · doi:10.3390/cancers15164125 · Cited by 23
“Despite improvements in RFS in major randomized trials like KEYNOTE-054 [56], KEYNOTE-716 [61], CheckMate-238 [55] and S1404 [64], no significant OS benefits have been demonstrated.”
BackgroundInfluentialImmunotherapy and urothelial carcinoma: An overview and future prospectives
Pierantoni, F., Maruzzo, M., Gardi, M., Bezzon, E., Gardiman, M. P., Porreca, A., Basso, U., & Zagonel, V. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.08.005 · Cited by 22
Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma
Rizk, E. M., Seffens, A., Trager, M. H., Moore, M. R., Geskin, L. J., Gartrell, R. D., Wong, W., & Saenger, Y. M. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00475-1 · Cited by 23
Cutaneous Melanoma – A Review of Systemic Therapies
Lee, K., & Nathan, P. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3496 · Cited by 24
“Adjuvant anti-PD-1 therapy has been tested in two large phase III studies, Checkmate 238 and Keynote 054, which have established nivolumab and pembrolizumab as the CPIs of choice for the adjuvant treatment of resected melanoma (60, 67).”
MethodVerver, D., Rekkas, A., Garbe, C., Klaveren, D. V., van Akkooi, A. C. J., Rutkowski, P. L., Powell, B. W. E. M., Robert, C., Testori, A., van Leeuwen, B. L., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.04.022 · Cited by 22
Self-citationDonini, M., Buti, S., Massari, F., Mollica, V., Rizzo, A., Montironi, R., Bersanelli, M., & Santoni, M. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1770601 · Cited by 23
“pembrolizumab [107] and nivolumab [108] as adjuvant thera-”
BackgroundImmuntherapie beim malignen Melanom
Zaremba, A., Zimmer, L., Griewank, K., Ugurel, S., Roesch, A., Schadendorf, D., & Livingstone, E. (2020) · Der Internist · doi:10.1007/s00108-020-00812-1 · Cited by 25
Self-citationSentinel Lymph Node Biopsy for T1b Melanoma: Balancing Prognostic Value and Cost
Hu, Y., Briggs, A. H., Gennarelli, R. L., Bartlett, E. K., Ariyan, C. E., Coit, D. G., & Brady, M. S. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08558-8 · Cited by 21
Shan, X., Yu, W., Ni, X., Xu, T., Lei, C., Liu, Z., Hu, X., Zhang, Y., Cai, B., & Wang, B. (2020) · Cancer Management and Research · doi:10.2147/cmar.s250479 · Cited by 21
“Recent studies on antiangiogenic and immune checkpoint therapies have provided promising results for melanoma inhibition.(2,3)”
Comparative Analysis of Acral Melanoma in Chinese and Caucasian Patients
Huang, K., Xu, Y., Gabriel, E. M., Misra, S., Chen, Y., Bagaria, S. P., & Asadi, A. K. (2020) · Journal of Skin Cancer · doi:10.1155/2020/5169051 · Cited by 26
“Evidence suggested that adjuvant systemic therapy especially new agents such as CTLA-4 blockade, an immune checkpoint inhibitor, has a sustained positive impact on DSS [24, 25].”
How we treat locoregional melanoma
Troiani, T., Falco, V. D., Napolitano, S., Trojaniello, C., & Ascierto, P. A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100136 · Cited by 25
Self-citationFujiwara, Y., Horita, N., Namkoong, H., & Galsky, M. D. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.012 · Cited by 23
Ouyang, T., Cao, Y., Kan, X., Chen, L., Ren, Y., Sun, T., Yan, L., Xiong, B., Liang, B., & Zheng, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.621639 · Cited by 23
Advances in the discovery and development of melanoma drug therapies
Chanda, M., & Cohen, M. S. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1942834 · Cited by 26
Bai, J., Li, D., Yang, P., Xu, K., Wang, Y., Li, Q., Liu, J., Du, W., Zhang, F., & Feng, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.778185 · Cited by 25
“ICI-induced neuromuscular side effects are rare but often severe and include musculoskeletal pain, myositis, polymyalgia rheumatica, ocular myositis, and MG. Myositis occurs in 1% of patients treated with PD-1 inhibitors (according to the prescribing information for Opdivo®) (19); there was one fatality in a trial of…”
BackgroundInborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1
Hao, Y., & Cook, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.806043 · Cited by 23
“8-2% of patients treated with pembrolizumab (98, 101, 102, 105) (Table 2).”
BackgroundAdjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases
Muto, Y., Kambayashi, Y., Kato, H., Fukushima, S., Ito, T., Maekawa, T., Fujisawa, Y., Yoshino, K., Uchi, H., Matsushita, S., et al. (2022) · Acta Dermato Venereologica · doi:10.2340/actadv.v102.678 · Cited by 21
“Adrenal insufficiency 1 (1) 4 (5) 0 (0) Abnormal hepatic function 0 (0) 3 (4) 0 (0) Diarrhoea 0 (0) 2 (3) 0 (0) Diabetic ketoacidosis 0 (0) 1 (1) 0 (0) Hypoparathyroidism 0 (0) 0 (0) 0 (0) Hypothyroidism 2 (3) 0 (0) 0 (0) Hyperthyroiditis 4 (5) 0 (0) 0 (0) Interstitial lung disease 4 (5) 1 (1) 0 (0) Increased creatini…”
BackgroundInfluentialHoellwerth, M., Koelblinger, P., Lang, R., & Harrer, A. (2023) · Life · doi:10.3390/life13020553 · Cited by 23
Surgery for Metastatic Melanoma: an Evolving Concept
Testori, A., Blankenstein, S. A., & van Akkooi, A. C. J. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0847-6 · Cited by 23
Acral melanoma in skin of color: current insights and future directions: a narrative review
Nadelmann, E., Singh, A., Abbruzzese, M., Adeuyan, O., Kenchappa, D., Kovrizhkin, K., Lightman, M., Samouha, A., Tao, K., Yun, J., et al. (2025) · Cancers · doi:10.3390/cancers17030468 · Cited by 20
“The additive effect of socioeconomic status on survival in ethnic minorities with ALM was highlighted by a Brazilian study showing correlation of income with survival [10].”
Immune checkpoint inhibition for the treatment of mesothelioma
Nowak, A. K., McDonnell, A. M., & Cook, A. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1606209 · Cited by 21
“checkpoint blockade is now also standard therapy in resected stage III melanoma [28].”
BackgroundMetabolic Interplay between the Immune System and Melanoma Cells: Therapeutic Implications
Indini, A., Grossi, F., Mandalà, M., Taverna, D., & Audrito, V. (2021) · Biomedicines · doi:10.3390/biomedicines9060607 · Cited by 22
“Anti-PD1 treatment has recently become standard of care in the adjuvant setting for patients with resected stage III (pembrolizumab or nivolumab) or stage IV melanoma with no evidence of disease (nivolumab) [10,11].”
BackgroundPedersen, S., Holmstroem, R. B., von Heymann, A., Tolstrup, L. K., Madsen, K. S., Petersen, M. A., Haslund, C. A., Ruhlmann, C. H. B., Schmidt, H., Johansen, C., et al. (2023) · Acta Oncologica · doi:10.1080/0284186x.2023.2165449 · Cited by 24
Guo, B., Chen, Q., Liu, Z., Chen, X., & Zhu, P. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1098958 · Cited by 23
“Similarly, some studies found that adjuvant PD-1 inhibitors also helpful in prolonging DFS for other cancers following surgery such as melanoma, esophageal, and gastroesophageal tumors (85, 86).”
ResultLooman, E. L., Cheng, P. F., Lai-Kwon, J. E., Morgan, L., Wakkee, M., Dummer, R., & Dimitriou, F. (2023) · Cancer Medicine · doi:10.1002/cam4.5967 · Cited by 20
Bertolli, E., Franke, V., Calsavara, V. F., de Macêdo, M. P., Pinto, C. A. L., van Houdt, W. J., Wouters, M. W. J. M., Neto, J. P. D., & van Akkooi, A. C. J. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-7038-9 · Cited by 20
Guillot, B., Dupuy, A., Pracht, M., Jeudy, G., Hindié, E., Desmedt, E., Jouary, T., & Leccia, M. ‐. (2019) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2019.01.011 · Cited by 25
Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response
Navani, V., Graves, M. C., Bowden, N. A., & van der Westhuizen, A. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14352 · Cited by 21
PD-L1 Expression Affects Neoantigen Presentation
Okada, M., Shimizu, K., Iyoda, T., Ueda, S., Shinga, J., Mochizuki, Y., Watanabe, T., Ohara, O., & Fujii, S. (2020) · iScience · doi:10.1016/j.isci.2020.101238 · Cited by 21
Immunotherapy for older patients with melanoma: From darkness to light?
Iacono, D., Vitale, M. G., Basile, D., Pelizzari, G., Cinausero, M., Poletto, E., Pascoletti, G., & Minisini, A. M. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12917 · Cited by 22
“Reports of real-life data demonstrated that no deterioration of efficacy is observed in elderly patients treated with immune TA B L E 2 Randomized phase III trials of immunotherapy in adjuvant setting (stage III) Study Design Main outcome (ITT) Elderly population Subgroup analysis KEYNOTE-054 Eggermont et al. (2018) P…”
BackgroundMethodInfluentialTumor-Infiltrating Lymphocyctes in Triple-Negative Breast Cancer: Update for 2020
Brown, L. C., Salgado, R., Luen, S. J., Savas, P. S., & Loi, S. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000501 · Cited by 22
miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors
Huemer, F., Leisch, M., Geisberger, R., Zaborsky, N., & Greil, R. (2021) · Pharmaceuticals · doi:10.3390/ph14020089 · Cited by 24
“Meanwhile, nivolumab [70], as well as pembrolizumab [71], have been FDA approved for adjuvant melanoma therapy in stage IIIB-IV and stage III, respectively.”
BackgroundChristofyllakis, K., Pföhler, C., Bewarder, M., Müller, F. M., Thurner, L., Rixecker, T. M., VOGT, T. M., Stilgenbauer, S., Yordanova, K., & Kaddu‐Mulindwa, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.637161 · Cited by 22
“Monotherapy with pembrolizumab or nivolumab have been shown to have a considerably better tolerability profile than ipilimumab (10, 24, 38).”
BackgroundBroman, K. K., Bettampadi, D., Pérez‐Morales, J., Sun, J. X., Kirichenko, D., Carr, M. J., Eroglu, Z., Tarhini, A. A., Khushalani, N. I., Schabath, M. B., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10570-5 · Cited by 21
Placke, J., Soun, C., Bottek, J., Herbst, R. A., Terheyden, P. A. M., Utikal, J. S., Pföhler, C., Ulrich, J., Kreuter, A., Pfeiffer, C., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.741993 · Cited by 20
Self-citationWeber, J. S., Ascierto, P. A., Middleton, M. R., Hennicken, D., Zoffoli, R., Pieters, A., Amadi, A., Kupas, K., Kotapati, S., Moshyk, A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.028 · Cited by 22
Self-citationNikita, N., Banks, J., Keith, S. W., Song, A. J., Johnson, J. M., Wilson, M. A., Sharma, S., & Lu-Yao, G. L. (2022) · Cancers · doi:10.3390/cancers14051296 · Cited by 23
Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma
Vercellino, L., de Jong, D., Dercle, L., Hosten, B., Braumuller, B., Das, J. P., Deng, A., Moya‐Plana, A., A’Keen, C. V., Yeh, R., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12051116 · Cited by 20
“Nodal involvement is one of the main prognostic factors in melanoma as N+ patients are considered as stage III by the Union for International Cancer Control (UICC), with a high risk of distant metastases, requiring adjuvant immunotherapy [24].”
BackgroundGratzke, C., Özgüroğlu, M., Peer, A., Şendur, M. A. N., Retz, M. M., Goh, J. C. H., Loidl, W. C., Jayram, G. T., Byun, S., Kwak, C. H., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.05.008 · Cited by 28
Yang, Y., Liu, J., Yang, K., Ma, Y., Fu, S., Tang, X., Wang, Y., & Zhou, L. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1804 · Cited by 21
Chronic Kidney Disease in Cancer Survivors
Lee, M. D., Wang, Q., Wanchoo, R., Eswarappa, M. S., Deshpande, P. P., & Sise, M. E. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.10.007 · Cited by 24
Alternatives and reduced need for sentinel lymph node biopsy (SLNB) staging for melanoma
van Akkooi, A. C. J., Schadendorf, D., & Eggermont, A. M. M. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.12.022 · Cited by 20
Self-citationImproving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma
Miller, J. R., Lo, S., Nosrati, M., Stretch, J. R., Spillane, A. J., Saw, R. P. M., Shannon, K. F., Nieweg, O. E., Ch’ng, S., Kim, K. B., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.6356 · Cited by 20
Vaios, E., Shenker, R. F., Hendrickson, P. G., Wan, Z., Niedzwiecki, D., Winter, S. F., Shih, H. A., Dietrich, J., Wang, C., Salama, A. K. S., et al. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.12.002 · Cited by 20
Egeler, M., Lai-Kwon, J. E., Tissier, R., Fraterman, I., Kuijpers, A. M. J., van Houdt, W. J., Wilgenhof, S., Rao, A. D., Sandhu, S. K., Lee, R. J., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113601 · Cited by 19
Self-citationIbrahim, A. M., May, M. L., Bossé, D., Marginean, H., Song, X., Nessim, C., & Ong, M. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08407-8 · Cited by 19
Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development
Oliveira, L. J. D. C., Gongora, A. B. L., & Jardim, D. L. F. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00928-5 · Cited by 20
Guía de práctica clínica de melanoma de la Academia Española de Dermatología y Venereología
Estrada, R. B., Boada, A., Carrera, C., Fernández‐Figueras, M. T., González‐Cao, M., Moreno-Ramírez, D., Nagore, E., Ríos‐Buceta, L., Rodríguez‐Peralto, J. L., Samaniego-González, E., et al. (2020) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2020.07.003 · Cited by 20
Li, H., Xu, J., Bai, Y., Zhang, S., Cheng, M., & Jin, J. (2021) · Investigational New Drugs · doi:10.1007/s10637-020-01039-5 · Cited by 19
Zhang, S., Zhou, Z., Wang, L., Li, M., Zhang, F., & Zeng, X. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320976996 · Cited by 22
Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma
Vanella, V., Festino, L., Vitale, M. G., Alfano, B., & Ascierto, P. A. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1901884 · Cited by 19
“Only one death in the pembrolizumab arm occurred, due to myositis [30].”
BackgroundSelf-citationTreatment of Metastatic Melanoma in the Elderly
Seedor, R. S., & Orloff, M. M. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01257-5 · Cited by 20
Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy
Margolis, N., Markovits, E., & Markel, G. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.06.005 · Cited by 20
Use of Immuno-Oncology in Melanoma
Smylie, M. (2020) · Current Oncology · doi:10.3747/co.27.5135 · Cited by 19
Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers
Tikkanen, A., Iivanainen, S., & Koivunen, J. P. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03217-7 · Cited by 19
Patients with Metastatic Melanoma Receiving Anticancer Drugs: Changes in Overall Survival, 2010–2017
Poizeau, F., Kerbrat, S., Happe, A., Rault, C., Drézen, E., Balusson, F., Tuppin, P., Guillot, B., Thuret, A., Boussemart, L., et al. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.07.038 · Cited by 19
Burton, E. M., Milton, D. R., Tetzlaff, M. T., Wani, K., Ross, M. I., Postow, M. A., Lazcano, R., Oliva, I. C. G., Wong, M. K., Patel, S. P., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00494 · Cited by 23
Min, D., Byun, J., Lee, E.-J., Khan, A. A., Liu, C., Loudig, O. D., Hu, W., Zhao, Y., Herlyn, M., Tycko, B., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0289 · Cited by 19
“Clinically available standard-of-care agents for targeted therapy and immunotherapy are now moving into the adjuvant setting (64, 65).”
BackgroundXavier, C. B., Lopes, C. D. H., Harada, G., Peres, E. D. B., Katz, A., & Jardim, D. L. F. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101383 · Cited by 21
The Role of Myeloid Cells in Hepatotoxicity Related to Cancer Immunotherapy
Gudd, C. L. C., & Possamai, L. A. (2022) · Cancers · doi:10.3390/cancers14081913 · Cited by 20
Atkinson, T. M., Hay, J. L., Kim, S. Y., Schofield, E., Postow, M. A., Momtaz, P., Warner, A. B., Shoushtari, A. N., Callahan, M. K., Wolchok, J. D., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac266 · Cited by 18
Wu, S., Fang, W., Chen, L., Feng, C., Chen, R., Ying, H., Zheng, X. W., & Jiang, J. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05460-0 · Cited by 20
Sentinel lymph nodes in melanoma: necessary as ever for optimal treatment
Faries, M. B. (2024) · Clinical & Experimental Metastasis · doi:10.1007/s10585-023-10254-2 · Cited by 18
“More recently, both targeted and immune checkpoint therapies have been developed and approved, making adjuvant therapy more broadly appealing [16, 17].”
BackgroundReview of recent advances in managing periocular skin malignancies
Trotier, D., Huang, L., van Landingham, S. W., Burr, A. R., & Ma, V. T.-L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1275930 · Cited by 19
Immune Checkpoint Inhibitors in Geriatric Oncology
Cook, S. L., Amin, M. A., Bari, S., Poonnen, P. J., Khasraw, M., & Johnson, M. O. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01528-3 · Cited by 19
“Older patients (> 65 years) comprise 22–50% of patients enrolled in landmark melanoma studies [38, 40–49], though this certainly remains under-representative given the increased incidence of melanoma with age.”
Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma
Menzies, A. M., Lo, S., Saw, R. P. M., Gonzalez, M., Ch’ng, S., Nieweg, O., Shannon, K. F., Ferguson, P. M., Lee, J., Emmett, L., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.05.002 · Cited by 19
Self-citationLi, J., & Gu, J. H. (2018) · Immunotherapy · doi:10.2217/imt-2018-0116 · Cited by 18
Revolutionizing treatment of advanced melanoma with immunotherapy
Carreau, N. A., & Pavlick, A. C. (2019) · Surgical Oncology · doi:10.1016/j.suronc.2019.01.002 · Cited by 22
How can clinical research improve European health outcomes in cancer?
Selby, P. J., Liu, L., Downing, A., Banks, I., Wilson, R., Stephens, R., Meunier, F., Rochon, J., Morris, E. J. A., Seymour, M., et al. (2019) · Journal of Cancer Policy · doi:10.1016/j.jcpo.2019.100182 · Cited by 18
Terheyden, P. A. M., Krackhardt, A. M., & Eigentler, T. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0497 · Cited by 32
“Pembrolizumab versus placebo EORTC 1325 (37)”
BackgroundMethodInfluentialBaetz, T. D., Fletcher, G. G., Knight, G. J., McWhirter, E., Rajagopal, S., Song, X., & Petrella, T. M. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102032 · Cited by 19
Gambichler, T., Tsagoudis, K., Kiecker, F., Reinhold, U., Stockfleth, E., Hamscho, R., Egberts, F., Hauschild, A., Amaral, T. M. S., & Garbe, C. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.10.016 · Cited by 18
Shao, B., Dang, Q., Chen, Z., Chen, C., Zhou, Q., Qiao, B., Liu, J., Hu, S., Wang, G., Yuan, W., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.760211 · Cited by 18
Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy
Davis, L., Tarduno, A., & Lu, Y. (2021) · Cancers · doi:10.3390/cancers13236061 · Cited by 19
Schwarze, J. K., Garaud, S., Jansen, Y. J. L., Awada, G., Vandersleyen, V., Tijtgat, J., de Wind, A., Kristanto, P., Seremet, T., Willard-Gallo, K. E., et al. (2022) · Cancers · doi:10.3390/cancers14030682 · Cited by 20
“As a result, anti-PD-1 immune checkpoint inhibitors (ICI) became the preferred adjuvant immuno-oncology treatment for melanoma patients [3,4].”
BackgroundResultBroman, K. K., Hughes, T. M., Bredbeck, B. C., Sun, J., Kirichenko, D., Carr, M. J., Sharma, A., Bartlett, E. K., Nijhuis, A. A. G., Thompson, J. F., et al. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005370 · Cited by 19
Lodde, G. C., Zimmer, L., Livingstone, E., Schadendorf, D., & Ugurel, S. (2020) · Der Pathologe · doi:10.1007/s00292-020-00776-x · Cited by 19
Self-citationLi, T., Jia, D., & Teng, L. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00913-6 · Cited by 20
Mitra, D., Ologun, G. O., Keung, E. Z.-Y., Goepfert, R. P., Amaria, R. N., Ross, M. I., Gershenwald, J. E., Lucci, A., Fisher, S. B., Davies, M. A., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-09804-3 · Cited by 18
Cancer immunotherapy does not increase the risk of death by COVID-19 in melanoma patientsPreprint
González‐Cao, M., Antonazas-Basa, M., Puértolas, T., Muñoz‐Couselo, E., Manzano, J. L., Carrera, C., Márquez‐Rodas, I., Criado, P. L., Rodríguez-Moreno, J. F., García‐Castaño, A., et al. (2020) · medRxiv · doi:10.1101/2020.05.19.20106971 · Cited by 18
Self-citationMontaño, M. A., Chagomerana, M., Borok, M. Z., Painschab, M., Uldrick, T. S., & Ignacio, R. B. (2021) · Current HIV/AIDS Reports · doi:10.1007/s11904-021-00542-5 · Cited by 17
Metadata
- Authors
- Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Maio, M., van den Eertwegh, A. J. M., Grob, J.-J., Gutzmer, R., Jamal, R., Lorigan, P., Ibrahim, N., Marreaud, S., van Akkooi, A. C. J., Suciu, S., & Robert, C.
- Affiliations
- Aix-Marseille Université (FR)
- From the Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif (A.M.M.E., C.R.), Hospices Civils de Lyon Cancer Institute, Cancer Research Center of Lyon, Lyon University, Lyon (S.D.), and Aix-Marseille University, Hôpital de la Timone, Assistance Publique–Hôpitaux de Marseille, Marseille (J.-J.G.) — all in France; Netherlands Cancer Institute–Antoni van Leeuwenhoek (C.U.B., A.C.J.A.) and VU University Medical Center (A.J.M.E.), Amsterdam, and Radboud University Medical...
- The University of Sydney (AU)
- The University of Queensland (AU)
- Edith Cowan University (AU)
- Washington University in St. Louis (US)
- University of Siena (IT)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Eggermont, Alexander M.M.
- Blank, Christian U.
- Long, Georgina V.
- Atkinson, Victoria
- Dalle, Stéphane
- Haydon, Andrew
- Khattak, Adnan
- Carlino, Matteo S.
- Sandhu, Shahneen
- Larkin, James
- Puig, Susana
- Ascierto, Paolo A.
- Rutkowski, Piotr
- Schadendorf, Dirk
- Koornstra, Rutger
- Hernandez-Aya, Leonel
- Maio, Michele
- Grob, Jean-Jacques
- Gutzmer, Ralf
- Jamal, Rahima
- Lorigan, Paul
- Ibrahim, Nageatte
- Marreaud, Sandrine
- Suciu, Stefan
- Robert, Caroline
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-10
- Volume
- 378
- Issue
- 19
- Pages
- 1789-1801
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2797309423
- Cited by
- 1,906
- References
- 31
- Citations by year
- 2026: 131 · 2025: 171 · 2024: 207 · 2023: 204 · 2022: 236 · 2021: 308 · 2020: 307 · 2019: 250 · 2018: 87
- FWCI
- 88.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Australasian Journal of Paramedicine (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
- Research Explorer (The University of Manchester) (submittedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, public-domain)
- Radboud Repository (Radboud University) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Merck Sharp and Dohme
- Topics
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- pembrolizumab, adjuvant therapy, stage III melanoma, PD-1 inhibitors, PD-L1 expression, recurrence-free survival, resected melanoma, immune checkpoint inhibitors, adverse events, myositis, non-relapse mortality, overall survival, progression-free survival, high-risk melanoma, tumor recurrence prevention, safety and tolerability
- MeSH terms
- Adjuvants, Immunologic, Adult, Aged, Aged, 80 and over, Double-Blind Method, Female, Humans, Infusions, Intravenous, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Skin Neoplasms, Survival Rate, Disease-Free Survival, Kaplan-Meier Estimate, Intention to Treat Analysis, B7-H1 Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.